Oncology
Guidelines, trial intelligence, mechanisms and education across oncology practice, from tumour-specific updates to systemic anticancer therapy evidence.
Latest Guidelines
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior lines of anti-HER2 treatment—use in treatment-naïve…
Nirogacestat for treating desmoid tumours
Nirogacestat is recommended as an option for treating desmoid tumours in adults when surgery is not suitable or has failed, enabling consideration of this gamma-secretase inhibitor…
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients who progress after prior…
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable
Ibrutinib combined with R-CHOP is recommended for untreated mantle cell lymphoma patients who are fit enough to undergo stem cell transplantation, offering improved outcomes compared to…
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based on individual patient factors…
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing prior to dostarlimab consideration,…
Trial Radar
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear…
PHASE3A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
What is being tested: Elritercept, a novel therapeutic agent, is being evaluated for its efficacy in reducing red…
PHASE3A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
A new cancer drug (sacituzumab tirumotecan) is being tested against standard treatment in advanced stomach cancer to see…
PHASE2Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
What is being tested: The combination of two immunotherapy agents—porustobart and pembrolizumab—administered before surgery (neoadjuvant approach) in patients…
Clinical News
Wellbeing support demand for cancer patients grows
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision…
23 Oct 2026First personalised cancer vaccine cuts risk of disease returning in major trial
Personalised cancer vaccines have demonstrated efficacy in reducing recurrence risk in clinical trials, representing a significant advance in…
23 Oct 2026‘Always remember, cancer doesn’t discriminate’
Cancer risk spans all demographics regardless of age, ethnicity, or background—screening and clinical vigilance should not be limited…
22 Oct 2026Haematology centre for cancer patients at risk over ‘disgraceful’ funds move
The Department of Health is withdrawing £1.5m funding from a haematology centre serving cancer patients in Belfast, creating…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismBTK Inhibition — B-cell Malignancies
BTK Inhibition — B-cell Malignancies is a clinically relevant Drug Science explainer. Bruton's tyrosine kinase (BTK) is a non-receptor cytoplasmic…
MechanismCDK4/6 Inhibition — Breast Cancer
CDK4/6 Inhibition — Breast Cancer is a clinically relevant Drug Science explainer. Cell cycle progression from G1 to S phase…
MechanismEGFR Pathway
EGFR Pathway is a clinically relevant Drug Science explainer. The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a transmembrane receptor tyrosine…
MechanismHER2 Signalling
HER2 Signalling is a clinically relevant Drug Science explainer. Human epidermal growth factor receptor 2 (HER2/ErbB2) is a receptor tyrosine…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Oncology education appears here when podcasts, webinars and CPD modules are tagged to this hub.
Useful starting points in Oncology
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear…
Clinical NewsWellbeing support demand for cancer patients grows
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision…
TrialA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
What is being tested: Elritercept, a novel therapeutic agent, is being evaluated for its efficacy in reducing red…
Education that still supports this area
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
WebinarJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
WebinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
Follow Oncology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Oncology
Choose guideline, trial, Drug Science and education updates for this specialty.